LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs kno
LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs known as selective oestrogen receptor modulators (SERMs) have been published in a meta-analysis in The Lancet by researchers from the United Kingdom, Italy and the USA. Jack Cuzick, Professor of Epidemiology at the Wolfson Institute of Preventive Medicine, Queen Mary University of London discussed the latest findings with Peter Goodwin and explained the background and some of the issues which have prevented this effective weapon against breast cancer being widely adopted until now.